
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
Frank Karbe, executive vice president and chief financial officer of Exelixis, reflects on some of the financial, regulatory, and intellectual property challenges facing the biopharma industry and shares his thoughts on what emerging leaders will need to do to address them.Listen to the Podcast for more coverage.






